Randomized trial comparing rabeprazole‐ versus lansoprazole‐based Helicobacter pylori eradication regimens

Abstract

Different types of proton pump inhibitor (PPI)-based triple therapies could result in different Helicobacter pylori eradication rates. This study aimed to compare the efficacy and safety of rabeprazole- and lansoprazole-based triple therapies in primary treatment of H. pylori infection. From September 2005 to July 2008, 426 H. pylori-infected patients were randomly assigned to receive a 7-day eradication therapy with either rabeprazole 20mgbid (RAC group, n=222) or lansoprazole 30mgbid (LAC group, n=228) in combination with amoxicillin 1gbid and clarithromycin 500mgbid. The patients received follow-up esophagogastroduodenoscopy (EGD) and/or (13)C-urea breath test 12-16 weeks later to define H. pylori status. Their personal and medical history, compliance and side effects were obtained by using a standardized questionnaire. Intention-to-treat analysis revealed that the eradication rate was 87.84% in the RAC group and 85.96% in the LAC group (p=0.56). All patients returned for assessment of compliance (100% in the LAC group vs. 99.50% in the RAC group; p=0.32) and adverse events (7.20% in the RAC group vs. 5.70% in the LAC group, p=0.51). Univariate analysis suggested that patients with nonsteroid anti-inflammatory agent (NSAID) use had lower eradication rates than those without (76.71% vs. 88.74%; p=0.006). Our results showed that efficacy and safety were similar in rabeprazole- and lansoprazole-based primary therapies. The influence of NSAID usage on H. pylori eradication needs to be further investigated.

REAP‐HP survey 2020: Comparing the real‐world practice and expectation in Helicobacter pylori eradication of the Taiwanese gastroenterologists in 2015 and 2020

“…[22][23][24][25][26][27] Although the 14-day stand triple therapy and 7-day standard triple therapy were the leading two most commonly used regimens of Taiwanese gastroenterologists, the pooled intention-to-treat eradication rates of the two regimens were only 84.6% (804/950) and 81.0% (949/1171), respectively. 17,[21][22][23][24][25][31][32][33] This confirmed that both 14-day standard triple therapy and 7-day standard triple therapy cannot achieve an eradication rate ≥90% in Taiwan, and do not meet the recommendations of most national or international consensuses. [28][29][30] In the Maastricht V/Florence Consensus Report 28 and the Taiwan H. pylori Consensus Report, 30 bismuth quadruple therapy and nonbismuth quadruple therapy are recommended first-line therapies for H. pylori infection in areas with high clarithromycin resistance (resistance rate ≥15%).…”

“…Although the 14‐day stand triple therapy and 7‐day standard triple therapy were the leading two most commonly used regimens of Taiwanese gastroenterologists, the pooled intention‐to‐treat eradication rates of the two regimens were only 84.6% (804/950) and 81.0% (949/1171), respectively 17,21–25,31–33 . This confirmed that both 14‐day standard triple therapy and 7‐day standard triple therapy cannot achieve an eradication rate ≥90% in Taiwan, and do not meet the recommendations of most national or international consensuses 28–30 …”

Real‐world practice and Expectation of Asia‐Pacific physicians and patients in Helicobacter Pylori eradication (REAP‐HP Survey)

“…). Finally, 26 clinical trials were eligible for analysis . In Taiwan, the 7‐day standard triple therapy was the most preferred first‐line therapy for H. pylori infection (Table ).…”

Sintesis reagen imunokimia untuk deteksi okratoksin dengan metode imunokromatografik nanopartikel emas Synthesis of immunochemical reagent for ochratoxin detection using gold nanoparticle immunochromatographic method

“…Bantalan absorben dilapiskan pada sisi plat yang lain. Zona uji dan kontrol dari membran nitroselulosa dilapisi berturut-turut dengan 0,25 µL konjugat OTA-OVA (0,1 mg/mL) dan 0,5 µL antibodi IgY (0,1 mg/mL) (modifikasi Liu et al, 2013).…”